Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 18, Number 9—September 2012
Research

Trends in Meningococcal Disease in the United States Military, 1971–2010

Michael P. BroderickComments to Author , Dennis J. Faix, Christian J. Hansen, and Patrick J. Blair
Author affiliations: Naval Health Research Center, San Diego, California, USA

Main Article

Figure 2

Proportion of each meningococcal serogroup among all isolates tested (1964–1984) or all cases (2006–2010), United States. Years of introduction of vaccine types are indicated by arrows. Unknown during 1964–1980 indicates isolates from a serogroup other than A/B/C/W135/Y or an unknown serogroup; during 1981–1984 indicates isolates that were not B, C, or Y; and during 2006–2010 indicates that no specimen is available and group is unknown. No data were available for 1985–2005. Data for 1964–1984 ar

Figure 2. . . . Proportion of each meningococcal serogroup among all isolates tested (1964–1984) or all cases (2006–2010), United States. Years of introduction of vaccine types are indicated by arrows. Unknown during 1964–1980 indicates isolates from a serogroup other than A/B/C/W135/Y or an unknown serogroup; during 1981–1984 indicates isolates that were not B, C, or Y; and during 2006–2010 indicates that no specimen is available and group is unknown. No data were available for 1985–2005. Data for 1964–1984 are from Brundage et al. (1) and Brundage and Zollinger (2). C, Neisseria meningitidis serogroup C; A, N. meningitidis serogroup A; quad, quadravalent (N. meningitidis serogroup s A, C, W-135, and Y).

Main Article

References
  1. Brundage  JF, Ryan  MA, Feighner  BH, Erdtmann  FJ. Meningococcal disease among United States military service members in relation to routine uses of vaccines with different serogroup-specific components, 1964–1998. Clin Infect Dis. 2002;35:137681. DOIPubMed
  2. Brundage  JF, Zollinger  WD. Evolution of meningococcal disease epidemiology in the US Army. In: Vedros NA, editor. Evolution of meningococcal disease, vol. I. Boca Raton (FL): CRC Press; 1987. p. 1885–1921.
  3. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) report, Emerging Infections Program Network, Neisseria meningitidis, 2009. 2010 [cited 2012 Jun 12]. http://www.cdc.gov/abcs/reports-findings/survreports/mening09.pdf
  4. Armed Forces Epidemiological Board Infectious Diseases Control Subcommittee. Vaccines in the military: a Department of Defense–wide review of vaccine policy and practice. A report of the Infectious Diseases Control Subcommittee of the Armed Forces Epidemiological Board. Falls Church (VA): The Board; 1999.
  5. Centers for Disease Control and Prevention. Meningococcal disease and college students. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49(RR-7):1320.PubMed
  6. Centers for Disease Control and Prevention. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;49(RR-7):110.
  7. Rubertone  MV, Brundage  JF. The Defense Medical Surveillance System and the Department of Defense Serum Repository: glimpses of the future of public health surveillance. Am J Public Health. 2002;92:19004. DOIPubMed
  8. Breslow  NE, Day  NE. Statistical methods in cancer research. Volume II—the design and analysis of cohort studies. Lyon (France): International Agency for Research on Cancer; 1987.
  9. Young  LS, LaForce  FM, Head  JJ, Feeley  JC, Bennett  JV. A simultaneous outbreak of meningococcal and influenza infections. N Engl J Med. 1972;287:59. DOIPubMed
  10. Moore  PS, Hierholzer  J, DeWitt  W, Gouan  K, Djore  D, Lippeveld  T, Respiratory viruses and mycoplasma as cofactors for epidemic group A meningococcal meningitis. JAMA. 1990;264:12715. DOIPubMed
  11. Rosenstein  NE, Perkins  BA, Stephens  DS, Popovic  T, Hughes  JM. Meningococcal disease. N Engl J Med. 2001;344:137888. DOIPubMed
  12. Crum  N, Chapman  FA, Russell  KL, Hale  BR. The many faces of meningococcal disease: a case series and review of presentations and treatment options. Infect Dis Clin Pract. 2005;13:59. DOI
  13. Artenstein  MS, Rust  JH Jr, Hunter  DH, Lamson  TH, Buescher  EL. Acute respiratory disease and meningococcal infection in army recruits. JAMA. 1967;201:10047. DOIPubMed
  14. Keyserling  HL, Pollard  AJ, DeTora  LM, Gilmet  GP. Experience with MCV-4, a meningococcal, diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135. Expert Rev Vaccines. 2006;5:44559. DOIPubMed
  15. Auckland  C, Gray  S, Borrow  R, Andrews  N, Goldblatt  D, Ramsay  M, Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis. 2006;194:174552. DOIPubMed
  16. Centers for Disease Control and Prevention. Updated recommendations for use of meningococcal conjugate vaccines—Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2011;60:726.PubMed
  17. Bilukha  OO, Rosenstein  N. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2005;54(RR-7):121.PubMed
  18. Bruce  MG, Rosenstein  NE, Capparella  JM, Shutt  KA, Perkins  BA, Collins  M. Risk factors for meningococcal disease in college students. JAMA. 2001;286:68893. DOIPubMed

Main Article

Page created: August 15, 2012
Page updated: August 15, 2012
Page reviewed: August 15, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external